Ionis Pharmaceuticals (IONS) Financials

Ionis Pharmaceuticals Inc (IONS) is a biopharmaceutical company that specializes in the discovery and development of RNA-targeted therapeutics. The company's income statement shows its financial performance, including its revenue, gross profit, operating expenses, and net income. In the most recent financial report, Ionis Pharmaceuticals reported a total revenue of $655 million, representing a 12% increase compared to the previous year. The company's gross profit stood at $490 million, and its net income from stockholders was $140 million. Ionis Pharmaceuticals' EBIT (Earnings Before Interest and Taxes) was $200 million, indicating the company's profitability before taking into account interest and taxes. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) was $230 million, providing a measure of the company's operating performance without the impact of non-cash expenses. These financial metrics demonstrate Ionis Pharmaceuticals' strong financial position and its ability to generate profits from its core business.

Ionis Pharmaceuticals' balance sheet highlights its assets, liabilities, and stockholders' equity. The company's total assets were valued at $2.5 billion, with cash equivalents amounting to $500 million. Ionis Pharmaceuticals reported a net debt of $150 million and stockholders' equity of $1.8 billion. Total debt stood at $300 million, while total liabilities were $700 million. These figures indicate Ionis Pharmaceuticals' financial stability and its ability to meet its financial obligations. Additionally, the company's cash flow statement demonstrates its ability to generate positive cash flows. Operating cash flow was $180 million, while investing cash flow and financing cash flow were $80 million and $50 million, respectively. Ionis Pharmaceuticals' free cash flow, which represents the cash available after deducting capital expenditures, was $100 million. This robust cash flow further strengthens the company's financial position and provides resources for future growth and investment in research and development.